Jessica Merrill
Senior Editor
Latest From Jessica Merrill
Teva Starts The Year With Phase III Data And Growth
Teva reported positive Phase III data for a long-acting version of olanzapine for schizophrenia, coinciding with its first quarter sales and earnings release.
With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way
The company initiated a rolling NDA submission for suzetrigine for acute pain, positioning the drug for a launch in 2025.
Pfizer Recruits Industry Analyst Baum To Advance Corporate Strategy
Longtime pharmaceutical industry analyst Andrew Baum will join Pfizer’s executive leadership team.
Dupixent COPD Approval Could Be Delayed, Regeneron Cautions
The US Food and Drug Administration has requested additional efficacy information on the supplemental filing in the potentially large new indication.
Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call
Pfizer’s management team addressed topics ranging from COVID-19 revenues to Medicare’s drug negotiation program and new product launches.
Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure
The Japanese pharmaceutical company will acquire Deciphera for $2.4bn, gaining GIST treatment Qinlock (ripretinib).